CEimpact Podcast

Pharmacotherapy Review of Narcolepsy

August 28, 2023 CEimpact
Pharmacotherapy Review of Narcolepsy
CEimpact Podcast
More Info
CEimpact Podcast
Pharmacotherapy Review of Narcolepsy
Aug 28, 2023
CEimpact

Narcolepsy can exact a devastating toll on the (probably underdiagnosed) patient. Treatment can range from lifestyle to medications. Join host, Geoff Wall, as he explores a new oral orexin agonist for the treatment of narcolepsy.
 
The GameChanger
Narcolepsy is more common than assumed. Current treatments include stimulant agents but a new class of orexin agonists may be effective, yet have safety concerns.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Dauvilliers Y, Mignot E, Del Río Villegas R, et al. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. N Engl J Med. 2023 Jul 27;389(4):309-321. doi: 10.1056/NEJMoa2301940. PMID: 37494485.

https://www.nejm.org/doi/full/10.1056/NEJMoa2301940?query=featured_home

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the manifestations, prevalence, and types of narcolepsy and associated symptoms.
2. Discuss the benefits and risks of orexin drugs in treatment of narcolepsy.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-292-H01-P
Initial release date: 8/28/2023
Expiration date: 8/28/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Show Notes

Narcolepsy can exact a devastating toll on the (probably underdiagnosed) patient. Treatment can range from lifestyle to medications. Join host, Geoff Wall, as he explores a new oral orexin agonist for the treatment of narcolepsy.
 
The GameChanger
Narcolepsy is more common than assumed. Current treatments include stimulant agents but a new class of orexin agonists may be effective, yet have safety concerns.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Dauvilliers Y, Mignot E, Del Río Villegas R, et al. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. N Engl J Med. 2023 Jul 27;389(4):309-321. doi: 10.1056/NEJMoa2301940. PMID: 37494485.

https://www.nejm.org/doi/full/10.1056/NEJMoa2301940?query=featured_home

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the manifestations, prevalence, and types of narcolepsy and associated symptoms.
2. Discuss the benefits and risks of orexin drugs in treatment of narcolepsy.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-292-H01-P
Initial release date: 8/28/2023
Expiration date: 8/28/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram